New Facility Assures Continuity of Supply of Anti-Obesity Treatment CONTRAVE®/MYSIMBA® Amidst GLP-1 Supply Issues
BRENTWOOD, TN, UNITED STATES, July 23, 2024 /EINPresswire.com/ -- Currax Pharmaceuticals LLC (“Currax”) today announced the approval of additional manufacturing site for CONTRAVE®/MYSIMBA® in the European Union (EU) and European Union Economic Areas (EEA …